Every time the AI Express is announced,恆瑞醫藥（SH 600276，收盤價：46.23元）3月26日晚間發佈公告稱，公司子公司蘇州盛迪亞生物醫藥有限公司、上海恆瑞醫藥有限公司、上海盛迪醫藥有限公司收到國家藥品監督管理局（以下簡稱“國家葯監局”）核准簽發關於注射用SHR-A2102、阿得貝利單抗注射液、貝伐珠單抗注射液的《藥物臨床試驗批准通知書》，將於近期開展臨床試驗。

2023年1至12月份，恆瑞醫藥的營業收入構成為：醫藥製造業佔比98.06%。

The chairman of Hengrui Pharmaceutical is Sun Piaoyang, male, 67 years old, with a doctorate degree.

截至發稿，恆瑞醫藥市值為2949億元。

Daoda1997 "Stock Trend" Alert:

30. In the past 0 days, no organization has conducted a survey on Hengrui Pharmaceutical.

每經頭條（nbdtoutiao）——It has been opposed by many car companies such as Geely and Weilai, and the ideal "list" is back! This time, there is only its own weekly sales, and there is no longer an industry ranking! Netizen: Look at what the child has become

(Reporter Wang Xiaobo)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Accordingly, do so at your own risk.

National Business Daily